EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Luminescent iridium(III)-pyridyl based complexes: tumor inhibitory studies in 4T1 mammary carcinoma mice model

Natesan Sundarmurthy Karthikeyan, Shishu Kant Suman, Prasad P. Phadnis, Lalrinawma Zote, Chandan Kumar, Vasanthakumaran Sudarsan

Exploration of Drug Science · 28.04.2026 · 4

DOI: 10.37349/eds.2026.1008158 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Exploration of Drug Science, online erschienen am 28.04.2026. Verfasst von Natesan Sundarmurthy Karthikeyan und 5 weiteren Autor:innen. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

The iridium(III) [Ir(III)] complexes exhibit anticancer properties, and along with their photoluminescence properties, they can be employed as diagnostic agents. Hence, we have tried to evaluate both properties. For this, the complexes of Ir(III) with pyridyl-based heterocyclic ligands, viz., [(TPQ)3Ir] (1), [(TPQ)2Ir(4-EO2-pic)] (2), and [(ppy)2Ir(dfpmpy)] (3) were prepared and evaluated for their cytotoxicity and emissive properties.

Methods

These complexes were authenticated by NMR (1H and 13C{1H}) spectroscopy and high-resolution mass spectrometry (HRMS). Their photophysical properties were evaluated by UV-Vis spectroscopy and photoluminescence studies. Among them, [(TPQ)3Ir] (1) and [(TPQ)2Ir(4-EO2-pic)] (2) complexes have exhibited red emission centred at ~600–625 nm range, which is appropriate for bio-imaging. The cellular internalization of [(TPQ)2Ir(4-EO2-pic)] (2) complex was investigated by confocal microscopy and flow cytometry at time intervals of 3 h and 6 h after its treatment with cancer cells. These Ir(III) complexes (1–3) were evaluated for their cytotoxicity against 4T1 mammary carcinoma cells by MTT assay. The moderately potent [(TPQ)2Ir(4-EO2-pic)] (2) complex was evaluated in vivo against 4T1 mammary carcinoma induced in BALB/c mice.

Results

Among these Ir(III) complexes (1–3), the [(TPQ)2Ir(4-EO2-pic)] (2) complex has exhibited moderate cytotoxicity (IC50 ~60 µM) as observed from their evaluations against triple-negative breast cancer (TNBC), a 4T1 mammary carcinoma cell line in vitro by MTT assay. Hence, its in vivo anticancer potency was evaluated by its treatment against 4T1 mammary carcinoma induced in BALB/c mice. This study exhibited tumor-inhibitory activity.

Conclusions

The [(TPQ)2Ir(4-EO2-pic)] (2) complex has exhibited a moderate tumor inhibitory property. The presented results have given us insights for designing and developing better Ir(III) complexes in our future endeavours.

Zitieren

APA

Karthikeyan, N. S., Suman, S. K., Phadnis, P. P., Zote, L., Kumar, C., & Sudarsan, V. (2026). Luminescent iridium(III)-pyridyl based complexes: tumor inhibitory studies in 4T1 mammary carcinoma mice model. Exploration of Drug Science, 4. https://doi.org/10.37349/eds.2026.1008158

Vancouver

Karthikeyan NS, Suman SK, Phadnis PP, Zote L, Kumar C, Sudarsan V. Luminescent iridium(III)-pyridyl based complexes: tumor inhibitory studies in 4T1 mammary carcinoma mice model. Exploration of Drug Science. 2026;4. doi:10.37349/eds.2026.1008158

BibTeX
@article{Karthikeyan2026,
  author = {Karthikeyan, Natesan Sundarmurthy and Suman, Shishu Kant and Phadnis, Prasad P. and Zote, Lalrinawma and Kumar, Chandan and Sudarsan, Vasanthakumaran},
  title = {Luminescent iridium(III)-pyridyl based complexes: tumor inhibitory studies in 4T1 mammary carcinoma mice model},
  journal = {Exploration of Drug Science},
  year = {2026},
  volume = {4},
  doi = {10.37349/eds.2026.1008158}
}
Kostenlos starten →